Bristol-Myers Competitors

Stocks . USA . 
Stock . Bristol Myers Squibb
CELG-RI Stock   0.10  0.01  8.11%   
Bristol Myers Squibb competes with NVIDIA, Apple, Alphabet, Microsoft, and Amazon; as well as few others. Analyzing Bristol-Myers Squibb competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Bristol-Myers Squibb to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Bristol-Myers Squibb Correlation with its peers.
For more detail on how to invest in Bristol-Myers Stock please use our How to Invest in Bristol-Myers Squibb guide.

Bristol-Myers Squibb vs Meta Platforms Correlation

Significant diversification

The correlation between Bristol Myers Squibb and META is 0.04 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and META in the same portfolio, assuming nothing else is changed.

Moving against Bristol-Myers Stock

  0.78AAPL Apple IncPairCorr
  0.51PBCRY Bank Central AsiaPairCorr
  0.43PTAIF PT Astra InternationalPairCorr
  0.37MSFT MicrosoftPairCorr
As of now, Bristol-Myers Squibb's Return On Tangible Assets are increasing as compared to previous years. The Bristol-Myers Squibb's current Return On Equity is estimated to increase to 0.62, while Return On Capital Employed is projected to decrease to 0.09. As of now, Bristol-Myers Squibb's Return On Tangible Assets are increasing as compared to previous years. The Bristol-Myers Squibb's current Debt To Assets is estimated to increase to 0.54, while Intangibles To Total Assets are projected to decrease to 0.32.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.0820.69
Details
Intrinsic
Valuation
LowRealHigh
0.000.0820.69
Details

Bristol-Myers Squibb Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Bristol-Myers Squibb and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Bristol-Myers and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Bristol Myers Squibb does not affect the price movement of the other competitor.

High positive correlations

TSM
+ 0.76
BMYMP
META
+ 0.59
GOOG
TSM
+ 0.56
GOOG
AMZN
+ 0.53
MSFT
BMYMP
+ 0.44
GOOG
META
+ 0.41
BMYMP
  

High negative correlations

TSM
- 0.79
MSFT
BMYMP
- 0.71
MSFT
TSM
- 0.49
AAPL
MSFT
- 0.43
GOOG
BMYMP
- 0.4
AMZN
META
- 0.38
MSFT

Risk-Adjusted Indicators

There is a big difference between Bristol-Myers Stock performing well and Bristol-Myers Squibb Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Bristol-Myers Squibb's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Bristol-Myers Squibb Competitive Analysis

The better you understand Bristol-Myers Squibb competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Bristol-Myers Squibb's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Bristol-Myers Squibb's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CELG-RI NVDA AAPL GOOG MSFT AMZN BMYMP TSM META
 8.11 
 0.10 
Bristol-Myers
 1.18 
 184.97 
NVIDIA
 3.17 
 263.88 
Apple
 1.05 
 302.82 
Alphabet
 1.11 
 396.86 
Microsoft
 1.19 
 201.15 
Amazon
 0.29 
 1,003 
Bristol-Myers
 0.59 
 364.20 
Taiwan
 0.07 
 639.29 
Meta
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Market Performance
(90 Days Performance)
Good
Weakest
Weakest
Soft
Weakest
Weakest
Good
Solid
Mild
Odds of Financial Distress
(Probability Of Bankruptcy)
Fair
Low
Tiny
Tiny
Low
Tiny
Low
Tiny
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Over Valued
Under Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Buy
Strong Buy
Strong Buy
Strong Buy
Not Available
Strong Buy
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Sell
Hold
Strong Hold
Strong Hold
Strong Hold
Strong Hold
Strong Sell
Strong Buy
Strong Hold
Current Ratio
N/A
3.39
0.88
2.52
1.84
0.94
1.4
2.49
2.52
Net Asset
N/A
111.6 B
359.24 B
595.28 B
619 B
818.04 B
109.31 B
7.91 T
366.02 B
Profit Margin
N/A
0.53
0.27
0.33
0.39
0.11
N/A
0.45
0.3
EBITDA
N/A
86.14 B
144.43 B
179.96 B
160.16 B
165.34 B
20.1 B
2.75 T
104.55 B
Operating Margin
N/A
0.63
0.35
0.32
0.47
0.11
N/A
0.54
0.41
Current Valuation
N/A
4.39 T
3.78 T
3.63 T
2.95 T
2.16 T
N/A
1.52 T
1.62 T
Price To Book
N/A
37.37
42.58
8.91
7.62
5.19
N/A
11.07
7.45
Retained Earnings
N/A
68.04 B
(14.26 B)
324.06 B
237.73 B
250.54 B
N/A
4.69 T
121.18 B
Current Asset
N/A
6.05 B
106.87 B
105.41 B
139.66 B
35.7 B
N/A
N/A
N/A
Five Year Return
N/A
0.2
1.0
N/A
1.18
N/A
N/A
2.64
N/A
Beta
N/A
2.31
1.11
1.09
1.08
1.39
0.35
1.27
1.28
Number Of Employees
N/A
36 K
150 K
190.82 K
228 K
1.58 M
23.7 K
83.83 K
78.86 K
Shares Outstanding
N/A
24.3 B
14.68 B
5.44 B
7.43 B
10.73 B
N/A
5.19 B
2.19 B
Cash Flow From Operations
N/A
64.09 B
111.48 B
164.71 B
136.16 B
139.51 B
16.21 B
2.38 T
115.8 B
Annual Yield
N/A
2.0E-4
0.0041
0.0027
0.0091
N/A
0.0012
0.0097
0.0033
Total Debt
N/A
10.27 B
112.38 B
72.03 B
60.59 B
152.99 B
39.6 B
990.36 B
83.9 B
Return On Equity
N/A
1.07
1.52
0.36
0.34
0.22
N/A
0.35
0.3
Return On Asset
N/A
0.54
0.24
0.15
0.15
0.0693
N/A
0.17
0.16
Number Of Shares Shorted
N/A
257.09 M
116.85 M
48.65 M
58.41 M
71.85 M
N/A
19.46 M
32.46 M
Book Value Per Share
N/A
4.89
6.0
34.35
52.62
38.31
7.55
6.66
85.87
Current Liabilities
N/A
2.35 B
79.01 B
16.76 B
59.36 B
33.89 B
N/A
N/A
N/A
Total Asset
N/A
111.6 B
359.24 B
595.28 B
619 B
818.04 B
109.31 B
7.91 T
366.02 B
Debt To Equity
N/A
0.56
2.61
0.12
0.44
1.2
59.4
0.31
0.13
Short Ratio
N/A
1.61
2.36
2.63
1.8
1.78
N/A
1.34
1.87
Target Price
N/A
253.88
292.15
359.24
596.0
282.17
N/A
421.49
860.08
Last Dividend Paid
N/A
0.04
1.03
0.83
3.48
N/A
1.59
N/A
2.1
Shares Owned By Institutions
N/A
69.82
65.48
61.24
76.46
66.96
N/A
15.88
79.09
Market Capitalization
N/A
4.45 T
3.76 T
3.7 T
2.98 T
2.13 T
2.11 T
1.9 T
1.62 T
Price To Earning
N/A
41.94
24.24
20.62
26.64
83.26
N/A
21.27
9.3
Price To Earnings To Growth
N/A
0.71
2.31
2.32
1.52
1.82
N/A
1.28
1.15
Price To Sales
N/A
23.78
8.63
9.19
9.77
2.98
N/A
0.5
8.05
Net Income
N/A
72.88 B
112.01 B
132.17 B
101.83 B
77.67 B
7.01 B
1.74 T
60.46 B
Earnings Per Share
N/A
4.04
7.9
10.8
15.97
7.18
N/A
10.55
23.48
Shares Owned By Insiders
N/A
4.33
1.71
6.64
0.072
9.14
N/A
0.04
0.07
Revenue
N/A
130.5 B
416.16 B
402.96 B
281.72 B
716.92 B
46.38 B
3.85 T
200.97 B
Working Capital
N/A
62.08 B
(17.67 B)
103.29 B
49.91 B
11.08 B
N/A
1.82 T
66.89 B
Cash And Equivalents
N/A
13.14 B
7.67 B
116.26 B
30.24 B
86.81 B
6.07 B
4.13 B
40.49 B
Cash Per Share
N/A
5.34
3.04
8.98
14.39
5.75
3.72
7.23
15.06
Gross Profit
N/A
131.09 B
206.16 B
240.3 B
209.5 B
360.51 B
N/A
2.28 T
164.79 B
Day Typical Price
0.0949
183.77
261.9
301.51
397.3
199.63
1001.95
362.21
636.9
Accumulation Distribution
1484.87
6.9 M
2.3 M
614299.0
478977.0
2 M
0.0029
272378.0
271788.0
Market Facilitation Index
0.0
N/A
N/A
N/A
N/A
N/A
2.93
0.0
0.0
Daily Balance Of Power
0.487
0.271
0.7535
(0.40)
(0.74)
0.4112
1.0
(0.22)
(0.03)
Period Momentum Indicator
0.0075
2.16
8.1
(3.20)
(4.46)
2.36
2.93
(2.16)
(0.48)
Rate Of Daily Change
1.08
1.01
1.03
0.99
0.99
1.01
1.0
0.99
1.0
Day Median Price
0.0923
183.17
260.92
300.86
397.53
198.87
1001.46
361.22
635.7
Price Action Indicator
0.0115
2.88
7.01
0.36
(2.89)
3.46
2.93
1.9
3.35
Coefficient Of Variation
534.07
(4,933)
(2,563)
2339.01
(542.42)
(576.89)
685.08
566.96
4088.07
Mean Deviation
13.65
1.66
0.9119
1.27
1.32
1.35
1.09
1.64
1.5
Jensen Alpha
3.62
(0.09)
(0.09)
0.0417
(0.38)
(0.35)
0.3092
0.301
0.0156
Total Risk Alpha
2.63
(0.17)
(0.14)
(0.03)
(0.47)
(0.41)
0.1852
0.2426
(0.07)
Sortino Ratio
0.2476
N/A
N/A
0.0124
N/A
N/A
0.0662
0.1618
(0.0002)
Downside Variance
219.0
N/A
N/A
2.09
N/A
N/A
15.08
3.71
2.44
Standard Deviation
19.86
2.13
1.37
1.66
1.92
1.78
2.13
2.07
2.16
Kurtosis
3.78
1.7
3.43
1.91
8.99
0.6118
9.25
0.1692
7.41
Potential Upside
38.02
2.95
2.6
2.82
1.9
2.53
4.04
3.48
3.43
Treynor Ratio
1.9
(0.06)
(0.10)
0.1363
(1.03)
(0.44)
(1.45)
0.2848
0.0677
Maximum Drawdown
129.02
10.08
9.06
9.42
13.28
8.93
13.48
9.62
13.69
Variance
394.26
4.55
1.86
2.75
3.68
3.15
4.52
4.27
4.65
Market Risk Adjusted Performance
1.91
(0.05)
(0.09)
0.1463
(1.02)
(0.43)
(1.44)
0.2948
0.0777
Risk Adjusted Performance
0.1584
(0.01)
(0.03)
0.0392
(0.14)
(0.13)
0.1223
0.1464
0.0258
Skewness
1.15
0.5241
(0.15)
0.7254
(2.03)
(0.44)
(0.33)
0.0274
1.99
Semi Deviation
12.32
N/A
N/A
1.38
N/A
N/A
1.4
1.72
1.52
Information Ratio
0.1846
(0.05)
(0.08)
0.0108
(0.21)
(0.20)
0.121
0.1507
(0.0001)
Value At Risk
(19.05)
(3.41)
(1.84)
(2.48)
(2.74)
(3.40)
(1.27)
(2.98)
(2.82)
Expected Short fall
(18.95)
N/A
N/A
(1.46)
N/A
N/A
(1.69)
(1.85)
(1.82)
Downside Deviation
14.8
N/A
N/A
1.44
N/A
N/A
3.88
1.92
1.56
Semi Variance
151.85
N/A
N/A
1.9
N/A
N/A
1.96
2.97
2.32

Bristol-Myers Squibb Competition Performance Charts

Five steps to successful analysis of Bristol-Myers Squibb Competition

Bristol-Myers Squibb's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Bristol Myers Squibb in relation to its competition. Bristol-Myers Squibb's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Bristol-Myers Squibb in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Bristol-Myers Squibb's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Bristol Myers Squibb, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Bristol-Myers Squibb position

In addition to having Bristol-Myers Squibb in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Investment Grade ETFs Thematic Idea Now

Investment Grade ETFs
Investment Grade ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Investment Grade ETFs theme has 335 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Investment Grade ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Bristol Myers Squibb offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bristol-Myers Squibb's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bristol Myers Squibb Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bristol Myers Squibb Stock:
How To Invest In Bristol-Myers
Details
Is Bristol-Myers Stock a good investment?
Details
What is Bristol-Myers Squibb's Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Bristol-Myers Squibb Correlation with its peers.
For more detail on how to invest in Bristol-Myers Stock please use our How to Invest in Bristol-Myers Squibb guide.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
It's important to distinguish between Bristol-Myers Squibb's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bristol-Myers Squibb should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY